Trial Profile
Phase I study of intrathecal rituximab in patients with recurrent CNS [central nervous system] lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 12 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrial.gov record.
- 01 Oct 2012 Planned end date 1 Jun 2013 added as reported by ClinicalTrials.gov.
- 02 Feb 2007 New trial record.